Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America.
ANN passed our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$31.64|
|52 Week High||AU$31.55|
|52 Week Low||AU$44.07|
|1 Month Change||-8.98%|
|3 Month Change||-23.59%|
|1 Year Change||-21.86%|
|3 Year Change||41.06%|
|5 Year Change||46.01%|
|Change since IPO||23.42%|
Recent News & Updates
Ansell Limited (ASX:ANN) Shares Could Be 38% Below Their Intrinsic Value Estimate
In this article we are going to estimate the intrinsic value of Ansell Limited ( ASX:ANN ) by projecting its future...
Do Ansell's (ASX:ANN) Earnings Warrant Your Attention?
Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Ansell (ASX:ANN) Has A Rock Solid Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Estimating The Intrinsic Value Of Ansell Limited (ASX:ANN)
Does the May share price for Ansell Limited ( ASX:ANN ) reflect what it's really worth? Today, we will estimate the...
|ANN||AU Medical Equipment||AU Market|
Return vs Industry: ANN underperformed the Australian Medical Equipment industry which returned -7.6% over the past year.
Return vs Market: ANN underperformed the Australian Market which returned 21.3% over the past year.
Stable Share Price: ANN is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: ANN's weekly volatility (4%) has been stable over the past year.
About the Company
Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by hospitals, surgical centers, dental practices, veterinary clinics, first responders, laboratories, and life sciences and pharmaceutical companies.
Ansell Fundamentals Summary
|ANN fundamental statistics|
Is ANN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ANN income statement (TTM)|
|Cost of Revenue||US$1.22b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
Feb 15, 2022
|Earnings per share (EPS)||2.01|
|Net Profit Margin||12.17%|
How did ANN perform over the long term?See historical performance and comparison
3.7%Current Dividend Yield
Is Ansell undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ANN (A$31.64) is trading below our estimate of fair value (A$57.41)
Significantly Below Fair Value: ANN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ANN is good value based on its PE Ratio (11.8x) compared to the Australian Medical Equipment industry average (13.6x).
PE vs Market: ANN is good value based on its PE Ratio (11.8x) compared to the Australian market (19.9x).
Price to Earnings Growth Ratio
PEG Ratio: ANN is poor value based on its PEG Ratio (56.2x)
Price to Book Ratio
PB vs Industry: ANN is good value based on its PB Ratio (1.9x) compared to the AU Medical Equipment industry average (4.5x).
How is Ansell forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ANN's forecast earnings growth (0.2% per year) is below the savings rate (1.9%).
Earnings vs Market: ANN's earnings (0.2% per year) are forecast to grow slower than the Australian market (11.5% per year).
High Growth Earnings: ANN's earnings are forecast to grow, but not significantly.
Revenue vs Market: ANN's revenue (1.4% per year) is forecast to grow slower than the Australian market (5.5% per year).
High Growth Revenue: ANN's revenue (1.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ANN's Return on Equity is forecast to be low in 3 years time (12.4%).
How has Ansell performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ANN has high quality earnings.
Growing Profit Margin: ANN's current net profit margins (12.2%) are higher than last year (9.7%).
Past Earnings Growth Analysis
Earnings Trend: ANN's earnings have grown by 11.7% per year over the past 5 years.
Accelerating Growth: ANN's earnings growth over the past year (57.5%) exceeds its 5-year average (11.7% per year).
Earnings vs Industry: ANN earnings growth over the past year (57.5%) underperformed the Medical Equipment industry 74.9%.
Return on Equity
High ROE: ANN's Return on Equity (15.9%) is considered low.
How is Ansell's financial position?
Financial Position Analysis
Short Term Liabilities: ANN's short term assets ($1.2B) exceed its short term liabilities ($549.9M).
Long Term Liabilities: ANN's short term assets ($1.2B) exceed its long term liabilities ($623.2M).
Debt to Equity History and Analysis
Debt Level: ANN's debt to equity ratio (28.9%) is considered satisfactory.
Reducing Debt: ANN's debt to equity ratio has reduced from 60.8% to 28.9% over the past 5 years.
Debt Coverage: ANN's debt is well covered by operating cash flow (38.3%).
Interest Coverage: ANN's interest payments on its debt are well covered by EBIT (19.6x coverage).
What is Ansell current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: ANN's dividend (3.69%) is higher than the bottom 25% of dividend payers in the Australian market (2.23%).
High Dividend: ANN's dividend (3.69%) is low compared to the top 25% of dividend payers in the Australian market (5.3%).
Stability and Growth of Payments
Stable Dividend: ANN's dividends per share have been stable in the past 10 years.
Growing Dividend: ANN's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (40%), ANN's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ANN's dividends in 3 years are forecast to be well covered by earnings (45.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Neil Salmon (52 yo)
Mr. Neil I. Salmon, BA, ACMA, serves as the Managing Director & Chief Executive Office at Ansell Limited since September 1, 2021 and serves as its Director since 2021. He served as the President of Industr...
CEO Compensation Analysis
Compensation vs Market: Neil's total compensation ($USD3.95M) is above average for companies of similar size in the Australian market ($USD1.83M).
Compensation vs Earnings: Neil's compensation has increased by more than 20% in the past year.
Experienced Management: ANN's management team is considered experienced (2.4 years average tenure).
Experienced Board: ANN's board of directors are considered experienced (4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ANN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Ansell Limited's employee growth, exchange listings and data sources
- Name: Ansell Limited
- Ticker: ANN
- Exchange: ASX
- Founded: 1893
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: AU$3.885b
- Shares outstanding: 122.78m
- Website: https://www.ansell.com
Number of Employees
- Ansell Limited
- 678 Victoria Street
- Level 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/24 07:02|
|End of Day Share Price||2021/10/22 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.